ARBE Arbe Robotics Ltd.
Price Chart
Executive Summary
Amerx initiated coverage on ARBE (Arbe Robotics Ltd.) with a Buy rating and a $2.21 price target, implying 160% upside from the current $0.85. The call aligns with a consensus that is 77.8% Buy (7 of 9 analysts), though the new target sits below the $2.50 mean. The firm has no tracked accuracy record, limiting its signaling power. Price targets span $1.50 to $3.50, with a median of $2.50. EPS revisions have been trending positive — the forward-year estimate improved from -$0.20 to -$0.13 over 30 days. However, insider sales by a C-suite executive totaling ~$233k over two days and a 59.3% short interest ratio create notable divergence from the bullish analyst read. The bottom line: the initiation is directionally in line with a bullish consensus, but insider selling and heavy short interest warrant caution for traders.
Impact Score
Consensus & Targets
Of 9 analysts covering ARBE, 2 rate it Strong Buy, 5 rate Buy, and 2 rate Hold — a 77.8% Buy-side consensus (including Strong Buy) and 22.2% Hold. There are no Sell ratings. The direction is firmly bullish.
Mean price target is $2.50, median $2.50, high $3.50 (from WestPark Capital), low $1.50 (from Canaccord Genuity). Current price $0.85 implies 194% upside to the mean. Amerx's $2.21 target is about 12% below the mean and above the low, placing it in the middle of the range.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-29 | Canaccord Genuity | maintain | Buy | $1.50 |
| 2026-05-11 | Amerx | initiate | Buy | $2.21 |
| 2026-02-27 | Canaccord Genuity | maintain | Buy | $1.25 |
| 2026-01-08 | WestPark Capital | initiate | Buy | $3.50 |
| 2025-11-18 | Canaccord Genuity | maintain | Buy | $1.75 |
| 2025-04-01 | Canaccord Genuity | initiate | Buy | $1.75 |
| 2025-03-06 | Maxim Group | downgrade | Hold | — |
Over the past 30 days, there were 0 upgrades and 0 downgrades. However, Canaccord Genuity maintained its Buy on 2026-05-29 with a $1.50 target. EPS revisions have been positive: the +1q estimate was revised up once in both 7-day and 30-day windows, and the one-year-forward EPS improved from -$0.20 to -$0.13 over 30 days. Estimates are being revised higher.
Firm Track Record — Amerx
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 1 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Canaccord Genuity | 50% | 1/2 | 22.9% | below average |
Amerx has no accuracy data on ARBE or any scored calls in the dataset, so its track record cannot be assessed. The only other firm with accuracy data is Canaccord Genuity, which is 50% accurate on 2 calls with a 22.9% average return, below average versus peers. No best/worst comparison is possible given limited data.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $-0.06 | $-0.06 — $-0.06 | $1.2M | ↑1 ↓0 |
| 0q | $-0.06 | $-0.06 — $-0.06 | $564.0K | ↑1 ↓0 |
| +1y | $-0.13 | $-0.13 — $-0.13 | $24.8M | ↑1 ↓0 |
| 0y | $-0.24 | $-0.24 — $-0.24 | $4.5M | ↑1 ↓0 |
Cross-Platform Signals
Insider trades show two sales by Arkind Noam (likely C-suite) on 2026-06-02 and 2026-06-03 totaling ~$233k — a bearish signal opposing the bullish initiation. No insider buys, congressional trades, or institutional position changes were recorded. Short interest is elevated at 59.3% of TRF volume, implying significant bearish positioning. This divergence between analyst bullishness and insider/short activity reduces conviction in the call.
Actionable Insight
The bullish initiation alone is not a strong standalone signal given the new firm's lack of track record and the insider selling. Traders should weigh the positive EPS revision trend and consensus support against the high short interest and insider sales before taking a directional position.
Documents Analyzed
Report based on filing metadata.
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
4d ago
|
ANALYST-UPGRADE
| $0.9304 awaiting T+5 | awaiting T+5 | — | $0.8780 (−5.63%) |
|
May 16, 2026
29d ago
|
ANALYST-DOWNGRADE
| $1.29 $1.22 | ▼ −5.43% | ▼ −3.17% | $0.8780 (−31.94%) |
|
May 11, 2026
4w ago
|
ANALYST-UPGRADE
| $0.8960 $1.00 | ▲ +11.61% | ▲ +11.69% | $0.8780 (−2.01%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $0.8150 $0.7910 | ▲ +2.94% | ▲ +3.86% | $0.8780 (−7.73%) |
|
Apr 16, 2026
8w ago
|
ANALYST-DOWNGRADE
| $0.8130 $0.7480 | ▼ −8.00% | ▼ −8.98% | $0.8780 (+8.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access